<DOC>
	<DOCNO>NCT01453361</DOCNO>
	<brief_summary>Preliminary study variety vaccine suggest target accessibility ( potential immunogenicity ) variety solid tumor immune direct approach . In effort overcome limitation immunostimulatory cancer vaccine , investigator design novel autologous vaccine address inability fully identify cancer associate antigen , antigen recognition immune system ( i.e . antigen immunogen ) , effector potency , cancer-induced resistance . In effort overcome limitation immunostimulatory cancer vaccine , investigator design novel dual-modulatory autologous whole cell vaccine , Vigil™ ( bi-shRNA furin GMCSF Autologous Tumor Cell Vaccine ) , incorporate rhGMCSF ( recombinant human GMCSF ) transgene bifunctional shRNAfurin ( block proprotein conversion active TGFb1 b2 ) 1 ) address inability fully identify cancer associate antigen , 2 ) effect antigen recognition immune system ( i.e . antigen immunogen ) , 3 ) enhance effector potency , 4 ) subvert endogenous cancer-induced immune resistance . The investigator also complete Phase I assessment Vigil™ vaccine 27 advance solid tumor patient ( 1.0 x 10e7 2.5 x 10e7 cells/injection/month maximum 12 vaccination ) experience significant adverse effect follow 131 vaccination , include 4 patient melanoma . Plasmid functionality , immune biomarker response , preliminary evidence anticancer activity observe . This Phase II study intradermal autologous Vigil™ cancer vaccine ( 1.0 x 10e7 cells/injection ; maximum 12 vaccination ) patient stag IIIc IV melanoma biopsy accessible lesion document blood intratumoral immune response assess correlation survival .</brief_summary>
	<brief_title>Phase II FANG™ Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>1 . Histologically confirm Stages IIIc IV melanoma . 2 . Has inform alternative ≥ secondline therapy current standard care . If conventional frontline therapy indicate acceptable patient , patient may participate review sponsor . 3 . Clinically ( medically ) indicate procedure ( i.e . biopsy lesion recurrent disease , palliative management via resection , thoracentesis , etc . ) collect viable tumor sufficient quantity ( `` golf ball size '' estimate weight ~ 30 gram , pleural and/or ascites fluid estimate volume ≥ 500mL ) vaccine processing . 4 . Recovered ≤ Grade 1 ( exclude alopecia ) clinically relevant toxicity relate prior therapy . 5 . Patients allow participate follow single prior CNS treatment stereotactic radiotherapy whole brain irradiation stable without steroid requirement ≥2 month follow ≥2 prior CNS treatment stereotactic radiotherapy whole brain irradiation stable without steroid requirement ≥4 month . 6 . Patients must `` statin '' drug ≥ 2 week prior initiation therapy . 7 . Age ≥18 year . 8 . ECOG performance status ( PS ) 01 . 9 . Estimated &gt; 4 month survival probability . 10 . Normal organ marrow function define : Absolute granulocyte count ≥1,500/mm3 Absolute lymphocyte count ≥500/mm3 Platelets ≥100,000/mm3 Total bilirubin ≤2 mg/dL AST ( SGOT ) /ALT ( SGPT ) ≤2x institutional upper limit normal Creatinine &lt; 1.5 mg/dL 11 . Ability understand willingness sign write informed consent document . 12 . Negative pregnancy test . 1 . Surgery involve general anesthesia , chemotherapy , radiotherapy , steroid therapy , immunotherapy within 4 week prior enter study . Collection lumenal tissue must avoid . 2 . Patient must receive investigational agent within 30 day prior study entry . 3 . Patients know active symptomatic brain metastasis . 4 . Patients compromise pulmonary disease . 5 . Short term ( &lt; 30 day ) concurrent systemic steroid ≤ 0.25 mg/kg prednisone per day ( maximum 7.5 mg/day ) bronchodilator ( inhaled steroid ) permit ; steroid regimen and/or immunosuppressive exclude . Patients require steroid follow previous CNS radiation metastatic disease exclude . 6 . Prior splenectomy . 7 . Prior malignancy ( exclude nonmelanoma carcinomas skin ) unless remission 2 year . 8 . Kaposi 's Sarcoma . 9 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 10 . Patients pregnant nursing . 11 . Patients know HIV . 12 . Patients chronic Hepatitis B C infection . 13 . Patients uncontrolled autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>FANG</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Vigil</keyword>
</DOC>